Most recent update: Tuesday, April 7, 2020 - 09:55

Bariatric News - Cookies & privacy policy

You are here


Brain response to liraglutide may inform future treatments

A preclinical study from the Perelman School of Medicine at the University of Pennsylvania, has shown how the weight loss drug, liraglutide, crosses the brain's blood barrier to engage with a region of the brainstem known as the nucleus tractus solitarius (NTS), which is responsible for balancing food intake and energy expenditure. Filling this gap meets a need that has become a priority for researchers looking for new treatments to help fight the increasing rates of obesity.

Studies demonstrate the effectiveness of post-op liraglutide

Liraglutide can be considered as a safe and effective adjunctive treatment to prevent weight regain after bariatric surgery, according to two studies presented at the UK’s Society for Endocrinology annual conference.

In the first study, ‘Efficacy of liraglutide in weight management post bariatric surgery patients: data from an Emirati cohort’, researchers from Imperial College London Diabetes Centre, Abu Dhabi, UAE, assessed the use of Liraglutide for relapse after bariatric surgery in an Emirati population.

Regular behavioural counselling leads to significant weight loss

Intensive behavioural therapy (IBT), which provides diet and physical activity counselling, is proven to help adults with obesity achieve meaningful weight loss in six to 12 months, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. The study is the first randomised controlled evaluation of the efficacy of IBT when implemented under the Centers for Medicare and Medicaid Services (CMS) coverage guidelines.

Liraglutide aids weight loss for patients with monogenic obesity

Researchers at the University of Copenhagen have discovered that people with a strong genetic predisposition for developing obesity (monogenic obesity) can lose weight with the help of liraglutide, a modified form of the appetite-inhibiting hormone GLP-1, naturally secreted from the intestines when eating.

Study compares effectiveness of weight-loss drugs

In an analysis that included nearly 30,000 overweight or obese adults, comparing with placebo, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were each associated with achieving at least 5 percent weight loss at 52 weeks, and phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss, according to a study appearing in the June 14 issue of JAMA.

Liraglutide adds non-diabetic overweight and obese

For people with prediabetes who are overweight or obese, adding 3.0mg of liraglutide for three years to a diet and exercise plan may lead to major health improvements, according to outcomes from the SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) trial, in a presentation, ‘OR36-1 Liraglutide 3.0 Mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Obesity or Overweight and Prediabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 3-Year Trial’, presented at ENDO 2016, the annual meeting of the Endocrine Society, in B

GLP-1 and EndoBarrier improves diabetes and obesity

Combining a temporary one-year intestinal bypass device with the drug liraglutide helps patients lose weight and improve their diabetes control better than using either the device or the drug alone, according to researchers from the United Kingdom. The one-year results of the two-year Randomisation to Endobarrier alone Versus with Incretin analogue in SustainEd Diabesity (REVISE-Diabesity) clinical trial and supported by the Association of British Clinical Diabetologists (ABCD), were presented at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

SCALE trial: Liraglutide assists diabetics in losing weight

Overweight and obese patients with type 2 diabetes who received a daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, lost more weight over 56 weeks compared with placebo, according to a study ‘Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes - The SCALE Diabetes Randomized Clinical Trial’, published in JAMA. Liraglutide is a medication approved for the treatment of type 2 diabetes (administered once daily at doses of 1.2mg and 1.8mg).

Liraglutide lowers weight and HbA1c in T2DM Arab patients

Liraglutide is effective in reducing weight, HbA1c as well as other metabolic parameters in Arab population with type2 diabetes, according to a study 'Liraglutide effect in reducing Hba1c and weight in Arab population with type2 diabetes, a prospective observational trial', published in the Journal of Diabetes & Metabolic Disorders. The investigators from the United Arab Emirates said that they believed this was the first trial ever conducted to specifically look at the efficacy of liraglutide in Arab population.

Liraglutide helps obese adults to lose weight effectively

Patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least 5 to 10% of their start weight, compared to patients on placebo who made similar lifestyle changes. Patients who achieved that weight loss also showed improvements on a number of health markers, compared to those who lost less, and the patients on liraglutide showed greater improvement on measures of blood sugar control and blood pressure. The results were presented at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.

Subscribe to RSS - liraglutide